Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Geographic Differences in Antimalarial Drug Efficacy in Uganda Are Explained by Differences in Endemicity and Not by Known Molecular Markers of Drug Resistance

6 Mar 2006

Abstract excerpt

BACKGROUND: Recent clinical trials from Uganda have shown that the risk of failure following antimalarial therapy varies geographically. We tested the hypothesis that geographic differences in the response to therapy could be explained by differences in the prevalence of known molecular markers of drug resistance. METHODS: Samples from 2084 patients treated with chloroquine (CQ) plus sulfadoxine-pyrimethamine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Malaria Research and Control
Share to Parasitic Diseases Research and Treatment
Share to Pharmaceutical Quality and Counterfeiting

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16518760
DOI: 10.1086/500951

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Geographic Differences in Antimalarial Drug Efficacy in Uganda Are Explained by Differences in Endemicity and Not by Known Molecular Markers of Drug ResistancePMID 16518760Read ↗

Temporal changes in prevalence of molecular markers mediating antimalarial drug resistance in a high malaria transmission setting in Uganda.Semantic proximity Read ↗

Changing Antimalarial Drug Resistance Patterns Identified by Surveillance at Three Sites in Uganda.Semantic proximity Read ↗

Sustained High Prevalence of Multiple Antimalarial Drug Resistance Markers in Uganda in 2023-24Semantic proximity Read ↗

Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda.Semantic proximity Read ↗

Associations between Aminoquinoline Resistance Genotypes and Clinical Presentations of Plasmodium falciparum Infection in Uganda.Semantic proximity Read ↗

Sustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023-2024.Semantic proximity Read ↗

Comparative impacts over 5 years of artemisinin-based combination therapies on Plasmodium falciparum polymorphisms that modulate drug sensitivity in Ugandan children.Semantic proximity Read ↗

Changes in susceptibility of Plasmodium falciparum to antimalarial drugs in Uganda over time: 2019-2024.Semantic proximity Read ↗

Geographical Variation in Antimalarial Drug Resistance Marker Prevalence Across the Southern African Elimination Eight RegionSemantic proximity Read ↗

Drug resistance mediating Plasmodium falciparum polymorphisms and clinical presentations of parasitaemic children in Uganda.Semantic proximity Read ↗

Methodological issues in the assessment of antimalarial drug treatment: analysis of 13 studies in eight African countries from 2001 to 2004.Semantic proximity Read ↗

Malaria transmission intensity and the rate of spread of chloroquine resistant Plasmodium falciparum: Why have theoretical models generated conflicting results?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.